|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||11.85 - 11.90|
|52 Week Range||6.30 - 12.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2018 - Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.90|
Categories: Yahoo FinanceGet free summary analysis Enzymotec Ltd. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 13.67 million, Net Earnings of USD 0.42 million. Gross margins widened from 66.03% to 69.53% compared to the same period last year, operating (EBITDA) margins now 7.02% from 1.27%. Change in operating cash ... Read more (Read more...)
HERZLIYA, Israel, Dec. 12, 2017-- Frutarom Industries Ltd., one of the world's 10 largest companies in the field of flavors and natural specialty fine ingredients, reports that the shareholders of Enzymotec ...
MIGDAL HA’ EMEQ, Israel, Dec. 11, 2017-- Enzymotec Ltd., a developer, manufacturer and marketer of innovative bio-active lipid ingredients and nutritional products, today announced that at Enzymotec’ s ...
The Migdal Haemeq, Israel-based company said it had net income of 2 cents per share. Earnings, adjusted for stock option expense and costs related to mergers and acquisitions, came to 7 cents per share. ...
Israeli flavour and fine ingredients company Frutarom Industries said on Sunday it agreed to acquire the 81 percent of special nutrition firm Enzymotec it doesn't already own for $11.9 a share, or about $168 million. Frutarom had acquired in prior transactions 19 percent of Enzymotec for $42 million, reflecting an average share price of $9.6 and announced its intention to make a tender offer for Enzymotec shares. Enzymotec will become a wholly owned subsidiary of Frutarom and be delisted from trading.
Categories: Yahoo FinanceGet free summary analysis Enzymotec Ltd. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 13.02 million, Net Earnings of USD -2.31 million. Gross margins narrowed from 69.99% to 50.24% compared to the same period last year, operating (EBITDA) margins now -14.43% from 6.99%. Change in operating cash ... Read more (Read more...)
Research Desk Line-up: Enzymotec Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Genetic ...
On a per-share basis, the Migdal Haemeq, Israel-based company said it had a loss of 10 cents. Losses, adjusted for stock option expense, came to 6 cents per share. The maker of lipid-based nutritional ...
NEW YORK, NY / ACCESSWIRE / August 16, 2017 / Enzymotec Ltd. (NASDAQ: ENZY ) will be discussing their earnings results in their Q2 Earnings Call to be held August 16, 2017 at 8:30 AM Eastern Time. To listen ...
Enzymotec (ENZY) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
The Migdal Ha Emeq, Israel-based company said it had profit of less than 1 cent on a per-share basis. Earnings, adjusted for stock option expense, came to 3 cents per share. The results missed Wall Street ...